NCT04657198 - Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

June 3, 2021

Study Completion Date

October 25, 2021

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL

RSVPreF3 OA investigational vaccine (GSK3844766A)

RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1 (18 months post-Dose 2 in the RSV OA=ADJ-002 parent study).

Trial Locations (10)

2610

GSK Investigational Site, Wilrijk

3000

GSK Investigational Site, Leuven

9000

GSK Investigational Site, Ghent

14609

GSK Investigational Site, Rochester

21075

GSK Investigational Site, Elkridge

28601

GSK Investigational Site, Hickory

29464

GSK Investigational Site, Mt. Pleasant

66219

GSK Investigational Site, Lenexa

68134

GSK Investigational Site, Omaha

78229

GSK Investigational Site, San Antonio